- Home
- PSNL vs KOD Comparison
PSNL vs KOD Comparison
Compare PSNL & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | KOD |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.8M | 795.5M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PSNL | KOD |
|---|---|---|
| Price | $9.24 | $25.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $10.71 | ★ $22.67 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $1.92 |
| 52 Week High | $11.40 | $31.18 |
Technical Indicators
Market Signals| Indicator | PSNL | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 48.41 |
| Support Level | $7.72 | $23.92 |
| Resistance Level | $8.14 | $31.18 |
| Average True Range (ATR) | 0.50 | 2.45 |
| MACD | 0.03 | -0.54 |
| Stochastic Oscillator | 99.37 | 34.71 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.